Zobrazeno 1 - 10
of 46
pro vyhledávání: '"William J Irvin"'
Autor:
Roy S Herbst, Naiyer Rizvi, Karen Kelly, Vassiliki A Papadimitrakopoulou, Natasha B Leighl, Mary W Redman, Fred R Hirsch, Philip C Mack, Lawrence H Schwartz, James L Wade, William J Irvin, Sreekanth C Reddy, Jeffrey Crawford, Jeffrey D Bradley, Thomas E Stinchcombe, Suresh S Ramalingam, Jieling Miao, Katherine Minichiello, David R Gandara
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
Externí odkaz:
https://doaj.org/article/aa42cd2cdcbe45b39c93537b9fab9f89
Autor:
Deloris J. Veney, Lai Y. Wei, Amanda E. Toland, Carolyn J. Presley, Heather L. Hampel, Tasleem J. Padamsee, Clara N. Lee, William J. Irvin Jr, Michael J. Bishop, James J. Kim, Shelly R. Hovick, Leigha A. Senter, Daniel G. Stover
Publikováno v:
Cancer Medicine, Vol 13, Iss 17, Pp n/a-n/a (2024)
Abstract Introduction Tumor genomic testing (TGT) is standard‐of‐care for most patients with advanced/metastatic cancer. Despite established guidelines, patient education prior to TGT is frequently omitted. The purpose of this study was to evalua
Externí odkaz:
https://doaj.org/article/0f51ff3d583d483a9f9096298c4b2656
Autor:
Charles E. Geyer, Jr, Gong Tang, Priya Rastogi, Vicente Valero, Stephen K. Chia, Erin F. Cobain, Elias Obeid, David B. Page, Andrew S. Poklepovic, William J. Irvin, Jr., Adam M. Brufsky, Irene L. Wapnir, Jennifer M. Suga, Eleftherios (Terry) Mamounas, Norman Wolmark
Publikováno v:
Cancer Research. 83:OT2-16
Background: The CLEOPATRA trial established trastuzumab, pertuzumab and a taxane (THP) as a standard of care for first line metastatic, HER2-positve breast cancer with median progression-free survival (PFS) of 18.7 months and median OS of 57 months.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::44c30999f9f5e15eb575e322ba770a07
https://doi.org/10.1158/1538-7445.sabcs22-ot2-16-05
https://doi.org/10.1158/1538-7445.sabcs22-ot2-16-05
Autor:
Antonio C. Wolff, Richard M. Myers, William Grizzle, Paul Haluska, Jennifer F. De Los Santos, Helen Krontiras, William J. Irvin, Julie R. Nangia, Catherine H. Van Poznak, Sujata Patil, Tiffany A. Traina, Anna M. Storniolo, Rita Nanda, Hope S. Rugo, Minetta C. Liu, Nancy U. Lin, Christos Vaklavas, Yufeng Li, Vandana G. Abramson, Katherine E. Varley, Andres Forero-Torres
Purpose: Tigatuzumab (TIG), an agonistic anti-DR5 antibody, triggers apoptosis in DR5+ human tumor cells without crosslinking. TIG has strong in vitro/in vivo activity against basal-like breast cancer cells enhanced by chemotherapy agents. This study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01aeb05ea0f9b666431db03db47907f2
https://doi.org/10.1158/1078-0432.c.6524804.v1
https://doi.org/10.1158/1078-0432.c.6524804.v1
Autor:
Daniel F. Hayes, Andres Forero-Torres, Antonio C. Wolff, Catherine H. Van Poznak, Christos Vaklavas, Tiffany A. Traina, Anna M. Storniolo, Julie R. Nangia, Rita Nanda, Minetta C. Liu, Nancy U. Lin, William J. Irvin, Vandana G. Abramson, Martha E. Brown, Dafydd G. Thomas, Kimberly Aung, Kelley M. Kidwell, Maria C. Muñiz, Yufeng Li, Costanza Paoletti
Purpose: Circulating tumor cells (CTC) are prognostic in metastatic breast cancer (MBC). We tested whether EpCAM-based capture system (CellSearch) is effective in patients with triple-negative (TN) MBC, and whether CTC apoptosis and clustering enhanc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc82a93b4e8341969db7d17885cb8b88
https://doi.org/10.1158/1078-0432.c.6524666
https://doi.org/10.1158/1078-0432.c.6524666
Autor:
Daniel F. Hayes, Andres Forero-Torres, Antonio C. Wolff, Catherine H. Van Poznak, Christos Vaklavas, Tiffany A. Traina, Anna M. Storniolo, Julie R. Nangia, Rita Nanda, Minetta C. Liu, Nancy U. Lin, William J. Irvin, Vandana G. Abramson, Martha E. Brown, Dafydd G. Thomas, Kimberly Aung, Kelley M. Kidwell, Maria C. Muñiz, Yufeng Li, Costanza Paoletti
Supplementary Figure 1-5. Supplementary Figure 1. Example of cluster image using the CellSearch® system. Supplementary Figure 2. REMARK diagram of the 19 patients who had elevated CTC (Group B/C) at baseline that were used to study "CTC-response". S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97e12e73b7c8b510c104658757ec14d6
https://doi.org/10.1158/1078-0432.22460996
https://doi.org/10.1158/1078-0432.22460996
Autor:
Antonio C. Wolff, Richard M. Myers, William Grizzle, Paul Haluska, Jennifer F. De Los Santos, Helen Krontiras, William J. Irvin, Julie R. Nangia, Catherine H. Van Poznak, Sujata Patil, Tiffany A. Traina, Anna M. Storniolo, Rita Nanda, Hope S. Rugo, Minetta C. Liu, Nancy U. Lin, Christos Vaklavas, Yufeng Li, Vandana G. Abramson, Katherine E. Varley, Andres Forero-Torres
1. Supplemental Data: Differential of Toxicity and Eligibility Critique.; 2. Supplemental Figure 1: Gene Expression in Patients With Response to Therapy.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c77e2fd7a84def7242af058231a6b81
https://doi.org/10.1158/1078-0432.22461524.v1
https://doi.org/10.1158/1078-0432.22461524.v1
Autor:
Daniel F. Hayes, Andres Forero-Torres, Antonio C. Wolff, Catherine H. Van Poznak, Christos Vaklavas, Tiffany A. Traina, Anna M. Storniolo, Julie R. Nangia, Rita Nanda, Minetta C. Liu, Nancy U. Lin, William J. Irvin, Vandana G. Abramson, Martha E. Brown, Dafydd G. Thomas, Kimberly Aung, Kelley M. Kidwell, Maria C. Muñiz, Yufeng Li, Costanza Paoletti
Supplementary Table 1. Table illustrating the criteria with which a cell was considered viable, or apoptotic either due to positive M-30 staining and/or visual evidence of apoptosis (nucleic condensat). Legend: Y= Yes, N= No
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4884d6463a9ce0c930f2de55666704a5
https://doi.org/10.1158/1078-0432.22460993
https://doi.org/10.1158/1078-0432.22460993
Autor:
Cheryl L. Perkins, Beverly Moy, Katherine E. Reeder-Hayes, R. Bryan Rumble, Steven E. Come, Julie R. Gralow, Laura Spring, Mariana Chavez-MacGregor, Ian E. Smith, Heather L. McArthur, Shaveta Vinayak, Kathryn J. Ruddy, Gabriel N. Hortobagyi, Nancy E. Davidson, Natalie R. Dickson, Sophie S. Turner, Michael A. Danso, Douglas Yee, Lisa A. Carey, Avan Armaghani, Angelo Di Leo, Paul Unger, William J. Irvin, Rita Nanda
Publikováno v:
Journal of Clinical Oncology. 39:3938-3958
PURPOSE This guideline updates recommendations of the ASCO guideline on chemotherapy and targeted therapy for patients with human epidermal growth factor receptor 2–negative metastatic breast cancer (MBC) that is either endocrine-pretreated or horm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc7b883ef6db13b62935fdd2624b967b
https://doi.org/10.1200/jco.21.01374
https://doi.org/10.1200/jco.21.01374
Autor:
Mark A. Socinski, William J. Irvin, Howard Jack West, Daniel Morgensztern, Nathan A. Pennell, Liza C. Villaruz, T. Stinchcombe, Hyman B. Muss, Jared Weiss, Carrie B. Lee, Allison M. Deal, Daniel S. Bradford, Chad V. Pecot, James P. Stevenson, Jeffrey Crane
Publikováno v:
Cancer. 126:1060-1067
Background The selection of later-line treatment for older patients with AJCC (version 7) stage IV non-small cell lung cancer (NSCLC) remains controversial. Nanoparticle albumin-bound (nab)-paclitaxel is approved with carboplatin for the first-line t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::34361ff1d82684e09d145eb3542c67dd
https://doi.org/10.1002/cncr.32573
https://doi.org/10.1002/cncr.32573